

Accepted Manuscript

Anti-Tumour Treatment

Front-line treatment of CLL in the era of novel agents

Tadeusz Robak, Stephan Stilgenbauer, Alessandra Tedeschi

PII: S0305-7372(16)30155-4

DOI: <http://dx.doi.org/10.1016/j.ctrv.2016.12.007>

Reference: YCTRV 1588

To appear in: *Cancer Treatment Reviews Cancer Treatment Reviews*


Received Date: 4 November 2016

Revised Date: 12 December 2016

Accepted Date: 20 December 2016

Please cite this article as: Robak, T., Stilgenbauer, S., Tedeschi, A., Front-line treatment of CLL in the era of novel agents, *Cancer Treatment Reviews Cancer Treatment Reviews* (2016), doi: <http://dx.doi.org/10.1016/j.ctrv.2016.12.007>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Front-line treatment of CLL in the era of novel agents

Tadeusz Robak¹, Stephan Stilgenbauer², Alessandra Tedeschi³

¹Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, 93-510 Lodz, ul. Ciołkowskiego 2, Poland
Tel. 48426895191; e-mail robaktad@csk.umed.lodz.pl

²Department of Internal Medicine III, Ulm University, Albert-Einstein-Allee 23
Ulm 89081, Germany; Stephan.Stilgenbauer@uniklinik-ulm.de

³Department of Hematology, Niguarda Cancer Center, Niguarda Hospital,
Piazza Ospedale Maggiore 3, 20162 Milano, Italy,
alessandra.tedeschi@ospedaleniguarda.it

Short title: **Front-line treatment of CLL**

Corresponding author:

Prof. Tadeusz Robak
Department of Hematology
Medical University of Lodz
Copernicus Memorial Hospital
93-510 Lodz
Ul. Ciołkowskiego 2, Poland
e-mail: robaktad@csk.umed.lodz.pl
tel: +48 42 689-51-91
fax: +48 42 689-51-92

Key words: Chronic lymphocytic leukaemia, first-line, Bruton's kinase inhibitor, Ibrutinib, elderly, PI3K δ inhibitor, idelalisib, venetoclax

Abstract

Although chemoimmunotherapy prolongs survival and as such, is the standard of care for treatment-naïve patients, its effectiveness may be reduced by

Download English Version:

<https://daneshyari.com/en/article/5697680>

Download Persian Version:

<https://daneshyari.com/article/5697680>

[Daneshyari.com](https://daneshyari.com)